OpenAI Partners with Novo Nordisk to Accelerate Prescription Drug Development
OpenAI has partnered with Novo Nordisk to use AI in accelerating drug discovery and development. This collaboration marks OpenAI's shift toward enterprise and pharmaceutical applications, following previous deals with companies like Moderna and Sanofi. The partnership is part of OpenAI's broader strategy to focus on revenue-generating sectors amid declining consumer market share.
Topics: AI in drug development corporate partnerships Novo Nordisk OpenAI pharmaceuticals